Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 7/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922178 | 0.77 | MAPT (0.57) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL29629511 | 0.76 | KDM4E (0.41) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL15720603 | 0.74 | MAPT (0.46) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL23788124 | 0.74 | MAPT (0.41) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL15720604 | 0.74 | MAPT (0.46) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL29629530 | 0.71 | HPGD (0.39) | MAPTKMT2ASMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL12297545 | 0.70 | MAPT (0.50) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL9422004 | 0.68 | CYP1B1 (0.50) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL9422003 | 0.68 | CYP1B1 (0.50) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20533359 | 0.67 | KMT2A (0.43) | MAPTKMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BTK, LYN, LCK | MAPT 3683/4885KMT2A 1339/4885SMN1; SMN2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.